CliffBio
small molecule

XOSPATA

GILTERITINIB FUMARATE

Loss of exclusivityJuly 2036latest FDA-listed patent expiry
CompanyAstellas Pharma Us →View the full company profile on CliffBio

Drug detail

Brand nameXOSPATA
Active ingredientGILTERITINIB FUMARATE
StrengthEQ 40MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusRX

Listed patents

PatentExpiresType
11938132July 2036product
11938133July 2036product
11944620July 2036product
11938130July 2036product
10786500July 2036product
11938131July 2036product
8969336November 2032substance, product
9487491July 2030use U-2456

More from Astellas Pharma Us

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XOSPATA patent cliff — loss of exclusivity July 2036 | CliffBio